Brief: Daxor Co Announces New Data From Duke Heart Validating Benefits Of Co's Bva-100 Blood Test In Optimizing Individualized Therapy For Heart Failure Patients
03/10/2022 13:34
Oct 3 (Reuters) - Daxor Corp DXR.O :
* DAXOR- CO ANNOUNCES NEW DATA FROM DUKE HEART VALIDATING
BENEFITS
OF CO'S BVA-100 BLOOD TEST IN OPTIMIZING INDIVIDUALIZED THERAPY
FOR HEART FAILURE PATIENTS
Source text for Eikon: ID:nGNX2VLZjK
Further company coverage: DXR.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Daxor
See all newsNASDAQ RESUMED AT 02:03 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:58 PM
Brief: Daxor Corp Reaffirms Focus On Blood Volume Analysis Technology
Brief: Daxor Corporation Submits 510(K) To FDA For Next-Generation Blood Volume Analyzer
Brief: Daxor Corporation Streamlines Regulatory Strategy For Groundbreaking Diagnostic Device